4/A: Akoya Biosciences CEO Brian McKelligon Reports Stock and Option Transactions
SEC Form 4/A
Brian McKelligon, CEO of Akoya Biosciences, reports acquisition of restricted stock units and stock options, as well as a disposition of shares to cover taxes.
Summary
- On February 22, 2024, Brian McKelligon, the President and CEO of Akoya Biosciences, acquired 87,500 shares of common stock and 175,000 employee stock options.
- The stock acquisition was in the form of restricted stock units.
- The restricted stock units vest in four equal annual installments starting March 1, 2025.
- Each restricted stock unit represents a right to receive one share of Akoya Biosciences common stock.
- The options vest 25% on February 22, 2025, and the remainder in 36 equal monthly installments starting March 22, 2025.
- On March 1, 2024, McKelligon disposed of 8,195 shares of common stock at $6.03 per share to cover taxes on a previously granted restricted stock unit award.
- Following these transactions, McKelligon directly owns 231,868 shares of Akoya Biosciences common stock and 175,000 employee stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment. The filing primarily reports routine stock and option transactions. The acquisition of equity can be seen as a positive, but the tax-related sale is neutral.
Positives
- The acquisition of restricted stock units and stock options by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.
Negatives
- The disposal of 8,195 shares to cover taxes, while a common practice, represents a small reduction in the CEO's holdings.
Future Outlook
The vesting schedules for the restricted stock units and stock options suggest a long-term commitment from the CEO to the company's success.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives regarding their ownership of company stock.
Stakeholder Impact
- The transactions may have a minor impact on shareholder sentiment, depending on how they interpret the CEO's actions.
Key Dates
| Date | Description |
|---|---|
| 02/22/2024 | Date of restricted stock unit and stock option acquisition. |
| 02/22/2025 | 25% of options vest. |
| 03/01/2024 | Date of share disposal for tax purposes. |
| 03/01/2025 | First vesting date for restricted stock units. |
| 03/22/2025 | Monthly vesting of remaining options begins. |
| 02/22/2034 | Expiration date of stock options. |
| 03/04/2024 | Date of Form 4/A filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.